Dr. Terkeltaub received his DCS (Biology) in 1972 and his MD (Medicine) in 1976, both at McGill University, Montreal, Canada.
Cartilage nucleotide metabolism and disease; the regulation of proinflammatory cytokine expression in macrophages.
- Johnson KA, Polewski M, Terkeltaub RA. Transglutaminase 2 is central to induction of the arterial calcification program by smooth muscle cells. Circulation Research, 14;102:529-37, 2008. PMCID: 2652242.
- Cecil DL, Terkeltaub R. Transamidation by Tranglutaminase 2 Transforms S100A11 Calgranulin into a Pro-Catabolic Cytokine for Chondrocytes. J Immunology, 180:8378-85, 2008. PMCID: 2577366.
- Cecil DL, Appleton TG, Polewski MD, Mort JS, Schmidt AM, Bendele A, Beier F, Terkeltaub R. The pattern recognition receptor CD36 is a chondrocyte hypertrophy marker but suppresses catabolic responses and promotes repair responses to inflammatory stimuli. J Immunology, 182:5024-31, 2009 PMCID: PMC2698125.
- Liu-Bryan R, Terkeltaub R. Chondrocyte Innate Immune MyD88-dependent Signaling Drives Pro-Catabolic Effects of the Endogenous TLR2/TLR4 Ligands LMW-HA and HMGB1. In Press, Arthritis Rheum, 2010.
- Terkeltaub R, Furst D, Bennett K, Kook KA, Crockett RS, Davis MW. Optimal dosing of oral colchicine for acute gout flare: Results of AGREE (Acute Gout Flare Receiving Colchicine Evaluation), the first randomized, placebo-controlled trial of low- vs. high-dose colchicine. In Press, Arthritis Rheum, 2010.
More Terkeltaub Publications via PubMed